Physician profile
Malia Downing
NPI 1013445071
$5,989.14
in general payments reported to CMS, 2019-2025
28 companies · $449 in 2025
The $449 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,719 · 2020: $232 · 2021: $638 · 2022: $335 · 2023: $543 · 2024: $2,073 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,966 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.84 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,229.64 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Kerecis Limited | $408.08 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Leo Pharma INC. | $384.69 | 2019-2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $362.70 | 2020-2025 | |
| Janssen Biotech, INC. | $315.62 | 2019-2025 | Tremfya |
| Allergan, INC. | $297.15 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $230.27 | 2022-2025 | Dupixent |
| Galderma Laboratories, L.P. | $213.51 | 2019-2025 | Aklief, Oracea, Epsolay |
| Lilly USA, LLC | $205.03 | 2021-2025 | Ebglyss, Taltz |
| Celgene Corporation | $168.41 | 2019 | |
| Genzyme Corporation | $155.99 | 2021-2024 | |
| Bioventus LLC | $155.64 | 2022 | |
| Janssen Scientific Affairs, LLC | $119.18 | 2019 | |
| Dermira, INC. | $117.07 | 2019 | |
| Sun Pharmaceutical Industries INC. | $111.09 | 2019-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $99.00 | 2025 | |
| Amgen INC. | $78.06 | 2020-2023 | Otezla |
| Pfizer INC. | $57.97 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $57.16 | 2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $56.85 | 2023-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.60 | 2019-2024 | Cabtreo |
| Ucb, INC. | $24.17 | 2024 | Bimzelx |
| Helsinn Therapeutics (U.S.), INC. | $23.58 | 2019 | |
| Fresenius Kabi USA, LLC | $17.38 | 2023 | |
| Merck Sharp & Dohme LLC | $17.24 | 2021 | |
| Dermavant Sciences, INC. | $16.97 | 2023 | Vtama |
| Incyte Corporation | $15.76 | 2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $13.33 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malia Downing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.